Empirica: Building a new model for brain cancer
Empirica is developing antibody therapeutics based on the biology of recurrence
Empirica is developing antibody-based therapies for glioblastoma multiforme using a mouse model built to mimic the biology of recurrent brain cancer, rather than that of primary tumors. Its lead candidate is a CAR T cell therapy that targets a biomarker of cancer stem cells.
Empirica Therapeutics Inc. CEO Sheila Singh said she sought to develop a better preclinical model for recurrent GBM after seeing many therapies for the indication